Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BP-C1 in Inoperable Pancreatic Cancer
NCT03627390Phase 2Completed
- Sponsor
- Meabco A/S
- Start
- Dec 2014
- Primary completion
- Mar 2016
- Modality
- Polymer-based Nanoparticles, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label trial of BP-C1 (2 arms), sponsored by Meabco A/S. Primary endpoints: Change (%) in the sum of diameters of target lesions at Day 32, Maximum Common Toxicity Criteria (CTC) score at Day 32 and 1 more. Started Dec 2014; status: completed.
02
Drugs
BP-C1
Beyond the preview
Go deeper on NCT03627390.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03627390.